Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

Eli Lil­ly $LLY is com­mis­sion­ing a small team in New Jer­sey to im­ple­ment its un­usu­al ap­proach to drug dis­cov­ery on a few of Lil­ly’s tar­gets, pay­ing out $30 mil­lion in an up­front fee plus some cash to get the re­search start­ed.

The new part­ner is An­i­ma Biotech, a tiny com­pa­ny that’s tar­get­ing dis­ease-caus­ing pro­teins way up­stream with a new class of drugs. The com­pa­ny’s co-founder and CEO Yochi Slonim de­scribes An­i­ma’s plat­form tech this way:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER